TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Mechanical and Oral Antibiotic Bowel Preparation Versus Oral Antibiotics Alone for the Reduction of Surgical Site Infection Following Elective Colorectal Resection
Brief Summary: This randomized clinical trial studies how well neomycin and metronidazole hydrochloride with or without polyethylene glycol work in reducing infection in patients undergoing elective colorectal surgery. Polyethylene glycol, may draw water from the body into the colon, flushing out the contents of the colon. Antibiotics, like neomycin and metronidazole hydrochloride, may stop bacteria from growing. It is not yet known whether it's better to give preoperative neomycin and metronidazole hydrochloride with or without polyethylene glycol in reducing surgical site infection after colorectal surgery.


Options:
A: Arm Label: Group A: IV and Oral antibiotics (IVA+OA); Type: ACTIVE_COMPARATOR; Interventions: Other: IVA+OA versus IVA+MBP+OA | Arm Label: Group B: IV antibiotics, MBP and oral antibiotics (IVA+MBP+OA); Type: ACTIVE_COMPARATOR; Interventions: Other: IVA+OA versus IVA+MBP+OA | Intervention Type: OTHER; Name: IVA+OA versus IVA+MBP+OA; Assigned to Arm(s): Group A: IV and Oral antibiotics (IVA+OA), Group B: IV antibiotics, MBP and oral antibiotics (IVA+MBP+OA)
B: Arm Label: Arm I (mechanical bowel prep, oral antibiotics); Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene Glycol, Drug: Neomycin, Drug: Metronidazole Hydrochloride, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (oral antibiotics); Type: EXPERIMENTAL; Interventions: Drug: Neomycin, Drug: Metronidazole Hydrochloride, Procedure: Therapeutic Conventional Surgery | Intervention Type: DRUG; Name: Polyethylene Glycol; Assigned to Arm(s): Arm I (mechanical bowel prep, oral antibiotics) | Intervention Type: DRUG; Name: Neomycin; Assigned to Arm(s): Arm I (mechanical bowel prep, oral antibiotics), Arm II (oral antibiotics) | Intervention Type: DRUG; Name: Metronidazole Hydrochloride; Assigned to Arm(s): Arm I (mechanical bowel prep, oral antibiotics), Arm II (oral antibiotics) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (mechanical bowel prep, oral antibiotics), Arm II (oral antibiotics)
C: Intervention Type: DRUG; Name: polyethylene glycol bowel lavage solution; Assigned to Arm(s): N/A
D: Arm Label: ornidazole; Type: EXPERIMENTAL; Interventions: Drug: ornidazole | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ornidazole; Assigned to Arm(s): ornidazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs; A Double-blind, Randomized, Placebo-controlled Trial
Brief Summary: The primary objective of this trial is to investigate whether intramuscular administration of allogeneic mesenchymal stromal cells (MSC) is safe and potentially effective, assessed as a composite outcome of mortality, limb status, clinical status (Rutherford classification) and pain score (visual analogue scale), in patients with no-option severe limb ischemia (SLI).

The investigators will conduct a double-blind, placebo-controlled randomized clinical trial to investigate the effect of allogeneic bone marrow(BM)-derived MSC in patients with SLI, who are not eligible for conventional surgical or endovascular therapies. The investigators intend to include 60 patients, who will be randomized to undergo 30 intramuscular injections with either BM-MSC (30 injection sites with 5\*10\^6 MSCs each) or placebo in the lower leg of the ischemic extremity. Primary outcome i.e. therapy success, a composite outcome considering mortality, limb status, clinical status (Rutherford classification) and changes in pain score, will be assessed at six months.


Options:
A: Intervention Type: GENETIC; Name: Autologous peripheral blood CD34 positive cell therapy; Assigned to Arm(s): N/A
B: Arm Label: Active/Treatment Group; Type: EXPERIMENTAL; Interventions: Biological: Allogeneic bone marrow derived mesenchymal stem cells | Arm Label: Observation Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 3; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Group 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Allogeneic bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Active/Treatment Group
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Intervention Type: PROCEDURE; Name: intraarterial stem cell therapy; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Stem cells; Assigned to Arm(s): 1, 2
D: Arm Label: Allogeneic Mesenchymal Stromal Cell; Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Stromal Cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Stromal Cell; Assigned to Arm(s): Allogeneic Mesenchymal Stromal Cell | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs; A Double-blind, Randomized, Placebo-controlled Trial
Brief Summary: The primary objective of this trial is to investigate whether intramuscular administration of allogeneic mesenchymal stromal cells (MSC) is safe and potentially effective, assessed as a composite outcome of mortality, limb status, clinical status (Rutherford classification) and pain score (visual analogue scale), in patients with no-option severe limb ischemia (SLI).

The investigators will conduct a double-blind, placebo-controlled randomized clinical trial to investigate the effect of allogeneic bone marrow(BM)-derived MSC in patients with SLI, who are not eligible for conventional surgical or endovascular therapies. The investigators intend to include 60 patients, who will be randomized to undergo 30 intramuscular injections with either BM-MSC (30 injection sites with 5\*10\^6 MSCs each) or placebo in the lower leg of the ischemic extremity. Primary outcome i.e. therapy success, a composite outcome considering mortality, limb status, clinical status (Rutherford classification) and changes in pain score, will be assessed at six months.


Options:
A: Intervention Type: DEVICE; Name: Bone marrow concentration device; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
C: Arm Label: mesenchymal stem cells; Type: EXPERIMENTAL; Interventions: Drug: mesenchymal stem cells | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Plasmalyte A | Intervention Type: DRUG; Name: mesenchymal stem cells; Assigned to Arm(s): mesenchymal stem cells | Intervention Type: DRUG; Name: Plasmalyte A; Assigned to Arm(s): Placebo
D: Arm Label: Allogeneic Mesenchymal Stromal Cell; Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Stromal Cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Stromal Cell; Assigned to Arm(s): Allogeneic Mesenchymal Stromal Cell | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Observational, Electronic Database With a Prospective Phase and Retrospective Phase for the Follow up of the ATG_FamilyStudy
Brief Summary: Allogeneic hematopoietic stem cell transplantation (HSCT) is capable of definitive cure of acute leukemias. The most important post-transplant complication is graft vs host disease (GVHD) which can be substantially decreased by the addition of anti-T lymphocyte globulin (ATG-Grafalon) to the standard GVHD prophylaxis (cyclosporin and methotrexate) without any increase in relapses and infections (Kroger et al NEJM 2016, ClinicalTrials.gov number, NCT00678275). In the ATG_familystudy (prospective, randomised, multicenter study) a decrease in the incidence of chronic GVHD (from 67.8% to 32.2%) was observed after the addition of ATG (10 mg/kg for three days ,from day -3 to -1) to the standard GVHD prophylaxis in the setting of acute leukemias in any remission, receiving peripheral blood stem cells from an HLA identical sibling donor after myeloablative preparative regimen. In particular, the GVHD extensive form was reduced from 52.4% to 7.6%. The study has been closed in 2014 with a minimum follow up of 2 years from transplant. The investigators would like to evaluate the longer term follow up of this study.


Options:
A: Arm Label: routine prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: anti thymoglobulin | Arm Label: ATG prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: anti thymoglobulin | Intervention Type: DRUG; Name: anti thymoglobulin; Assigned to Arm(s): ATG prophylaxis, routine prophylaxis
B: Arm Label: ATLG group; Type: N/A; Interventions: N/A | Arm Label: no ATLG group; Type: N/A; Interventions: N/A
C: Arm Label: Thymoglobulin; Type: EXPERIMENTAL; Interventions: Biological: Anti-Thymocyte Globulin (Rabbit) | Arm Label: No Thymoglobulin; Type: OTHER; Interventions: Other: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin) | Intervention Type: BIOLOGICAL; Name: Anti-Thymocyte Globulin (Rabbit); Assigned to Arm(s): Thymoglobulin | Intervention Type: OTHER; Name: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin); Assigned to Arm(s): No Thymoglobulin
D: Arm Label: A; Type: OTHER; Interventions: Drug: ATG FRESENIUS (Anti-Lymphocyte-Globulin) | Arm Label: B; Type: OTHER; Interventions: Drug: ATG FRESENIUS (Anti-Lymphocyte-Globulin) | Intervention Type: DRUG; Name: ATG FRESENIUS (Anti-Lymphocyte-Globulin); Assigned to Arm(s): A | Intervention Type: DRUG; Name: ATG FRESENIUS (Anti-Lymphocyte-Globulin); Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Testing the Leadership and Organizational Change for Implementation (LOCI) Intervention in Substance Abuse Treatment Programs
Brief Summary: This study will test the effects of the Leadership and Organizational Change for Implementation (LOCI) intervention in facilitating evidence-based practice (EBP) implementation in substance use disorder (SUD) and HIV services settings. LOCI improves implementation leadership and organizational support to develop strategic climate for EBP implementation. Greater efficiency and effectiveness of EBP implementation will improve the public health impact of evidence-based health and allied healthcare innovations and lead to greater effectiveness of SUD and HIV services.

Project Terms:


Options:
A: Arm Label: LOCI; Type: EXPERIMENTAL; Interventions: Behavioral: LOCI | Arm Label: Internet Based Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Internet Based Webinar Leadership Training | Intervention Type: BEHAVIORAL; Name: LOCI; Assigned to Arm(s): LOCI | Intervention Type: BEHAVIORAL; Name: Internet Based Webinar Leadership Training; Assigned to Arm(s): Internet Based Training
B: Arm Label: Educational Intervention; Type: EXPERIMENTAL; Interventions: Other: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance | Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Other: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance | Intervention Type: OTHER; Name: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance; Assigned to Arm(s): CONTROL, Educational Intervention
C: Arm Label: Tele-intensivist consultation; Type: EXPERIMENTAL; Interventions: Other: Tele-intensivist consultation | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Simulated "observation" by ICU physician | Intervention Type: OTHER; Name: Tele-intensivist consultation; Assigned to Arm(s): Tele-intensivist consultation | Intervention Type: OTHER; Name: Simulated "observation" by ICU physician; Assigned to Arm(s): Control
D: Arm Label: Retreat; Type: EXPERIMENTAL; Interventions: Other: Retreat | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Retreat; Assigned to Arm(s): Retreat

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Assess the Effectiveness of Intermittent Pneumatic Compression in the Prevention of Postoperative Venous Thromboembolism in Surgical Patients at Extremely High Risk
Brief Summary: The aim of the study is to evaluate efficacy and safety of venous thromboembolism prophylaxis by the combination of graduated compression stockings (GCS), standard doses of low-molecular-weight heparins (LMWH) and sequential compression device (SCD) in the mixed group of surgical patients at high and extremely high risk for venous thromboembolism.


Options:
A: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
B: Arm Label: Intermittent Pneumatic Compression(IPC); Type: EXPERIMENTAL; Interventions: Device: pneumatic compression | Arm Label: No Intermittent Pneumatic Compression; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pneumatic compression; Assigned to Arm(s): Intermittent Pneumatic Compression(IPC)
C: Arm Label: Experimental group (SCD + GCS + LMWH); Type: EXPERIMENTAL; Interventions: Device: SCD, Device: GCS, Drug: LMWH | Arm Label: Control group (GCS + LMWH); Type: ACTIVE_COMPARATOR; Interventions: Device: GCS, Drug: LMWH | Intervention Type: DEVICE; Name: SCD; Assigned to Arm(s): Experimental group (SCD + GCS + LMWH) | Intervention Type: DEVICE; Name: GCS; Assigned to Arm(s): Control group (GCS + LMWH), Experimental group (SCD + GCS + LMWH) | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): Control group (GCS + LMWH), Experimental group (SCD + GCS + LMWH)
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer - An Open Label, Non-comparative, Randomized, Multicenter Phase II Trial
Brief Summary: AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial


Options:
A: Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: cediranib, Drug: gemcitabine | Arm Label: Arm A; Type: PLACEBO_COMPARATOR; Interventions: Drug: gemcitabine, Drug: cisplatin, Drug: Placebo | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: cediranib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): B
B: Arm Label: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Type: EXPERIMENTAL; Interventions: Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A) | Arm Label: Arm Cisplatin + Gemcitabine (Arm B, standard of care); Type: OTHER; Interventions: Drug: Arm Cisplatin + Gemcitabine (Arm B) | Intervention Type: DRUG; Name: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Assigned to Arm(s): Arm NaI-IRI + 5-FU + Leucovorin (Arm A) | Intervention Type: DRUG; Name: Arm Cisplatin + Gemcitabine (Arm B); Assigned to Arm(s): Arm Cisplatin + Gemcitabine (Arm B, standard of care)
C: Arm Label: SP treatment; Type: EXPERIMENTAL; Interventions: Drug: S-1 plus cisplatin | Arm Label: GP treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: S-1 plus cisplatin; Assigned to Arm(s): SP treatment | Intervention Type: DRUG; Name: Gemcitabine plus Cisplatin; Assigned to Arm(s): GP treatment
D: Arm Label: A - Gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine hydrochloride | Arm Label: B - Gemcitabine and Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: gemcitabine hydrochloride | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): B - Gemcitabine and Cisplatin | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): A - Gemcitabine, B - Gemcitabine and Cisplatin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study
Brief Summary: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study


Options:
A: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
B: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Dalteparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin
C: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
D: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study
Brief Summary: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study


Options:
A: Arm Label: BAY59-7939; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Standard of Care; Type: EXPERIMENTAL; Interventions: Drug: Standard of Care | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): BAY59-7939 | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): BAY59-7939 | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Dalteparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin
C: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: B